Multidrug resistance in locally advanced breast cancer

被引:27
作者
Atalay, Can
Gurhan, Ismet Deliloglu
Irkkan, Cigdem
Gunduz, Ufuk
机构
[1] Ankara Oncol Hosp, Dept Gen Surg, Ankara, Turkey
[2] Ankara Oncol Hosp, Dept Pathol, Ankara, Turkey
[3] Middle E Tech Univ, Dept Biol, TR-06531 Ankara, Turkey
[4] Ege Univ, Dept Bioengn, Izmir, Turkey
关键词
breast cancer; ABCB1; ABCC1; multidrug resistance; multidrug resistance-associated protein 1; P-glycoprotein;
D O I
10.1159/000096086
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Advanced breast cancer cases can still be encountered resulting in poor prognosis. The primary treatment for these patients is chemotherapy, and multidrug resistance (MDR) is a serious obstacle in the treatment. Detecting drug resistance before first-line chemotherapy may increase the patient's survival. In this study, the role of MDR is evaluated in locally advanced breast cancer patients. Methods: Reverse transcriptase polymerase chain reaction was used for the detection of MDR genes, ABCB1 and ABCC1. Immunohistochemistry was used for the detection of MDR proteins, P-glycoprotein (Pgp) and MDR-associated protein 1. Results: Breast tissues from 25 patients both before and after chemotherapy were examined. Five patients were unresponsive to chemotherapy. Four had ABCB1 gene expression induced by chemotherapy, and Pgp positivity was detected in 9 patients after chemotherapy. Both the induction of ABCB1 gene expression (p < 0.001) and Pgp positivity (p < 0.001) during chemotherapy were significantly related with clinical response. Although 80% of the clinically unresponsive patients had ABCC1 gene expression, the relation between ABCC1 expression and clinical drug response was not significant. Conclusion: In locally advanced breast cancer, ABCB1 gene expression during chemotherapy contributes to clinical unresponsiveness. However, ABCC1 gene expression did not correlate strongly with the clinical response. Copyright (c) 2006 S. Karger AG, Basel
引用
收藏
页码:309 / 318
页数:10
相关论文
共 35 条
[1]   Predictive value of 99mTc sestamibi scintigraphy in the evaluation of doxorubicin based chemotherapy response in patients with advanced breast cancer [J].
Alonso, O ;
Delgado, L ;
Núñez, M ;
Vargas, C ;
Lopera, J ;
Andruskevicius, P ;
Sabini, G ;
Gaudiano, J ;
Musé, IM ;
Roca, R .
NUCLEAR MEDICINE COMMUNICATIONS, 2002, 23 (08) :765-771
[2]   P-glycoprotein: from genomics to mechanism [J].
Ambudkar, SV ;
Kimchi-Sarfaty, C ;
Sauna, ZE ;
Gottesman, MM .
ONCOGENE, 2003, 22 (47) :7468-7485
[3]   Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer [J].
Arnal, M ;
Franco, N ;
Fargeot, P ;
Riedinger, JM ;
Brunet-Lecomte, P ;
Lizard-Nacol, S .
BREAST CANCER RESEARCH AND TREATMENT, 2000, 61 (01) :13-20
[4]  
Beck WT, 1996, CANCER RES, V56, P3010
[5]   PCNA CYCLIN AND P-GLYCOPROTEIN AS PROGNOSTIC FACTORS IN LOCALLY ADVANCED BREAST-CANCER - AN IMMUNOHISTOCHEMICAL, RETROSPECTIVE STUDY [J].
BOTTI, G ;
CHIAPPETTA, G ;
DAIUTO, G ;
DEANGELIS, E ;
DEMATTEIS, A ;
MONTELLA, M ;
PICONE, A ;
CASCIONE, F .
TUMORI, 1993, 79 (03) :214-218
[6]  
Burger H, 2003, CLIN CANCER RES, V9, P827
[7]  
Cayre A, 2002, INT J ONCOL, V20, P1049
[8]   Multidrug resistance ABC transporters [J].
Chang, G .
FEBS LETTERS, 2003, 555 (01) :102-105
[9]   QUANTITATIVE IMMUNOCYTOCHEMICAL ASSAYS OF P-GLYCOPROTEIN IN BREAST CARCINOMAS - CORRELATION TO MESSENGER-RNA EXPRESSION AND TO IMMUNOHISTOCHEMICAL PROGNOSTIC INDICATORS [J].
CHARPIN, C ;
VIELH, P ;
DUFFAUD, F ;
DEVICTOR, B ;
ANDRAC, L ;
LAVAUT, MN ;
ALLASIA, C ;
HORSCHOWSKI, N ;
PIANA, L .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (20) :1539-1545
[10]   INTERNAL DUPLICATION AND HOMOLOGY WITH BACTERIAL TRANSPORT PROTEINS IN THE MDR1 (P-GLYCOPROTEIN) GENE FROM MULTIDRUG-RESISTANT HUMAN-CELLS [J].
CHEN, CJ ;
CHIN, JE ;
UEDA, K ;
CLARK, DP ;
PASTAN, I ;
GOTTESMAN, MM ;
RONINSON, IB .
CELL, 1986, 47 (03) :381-389